TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02240303

Intervention type: PROCEDURE
Intervention: Quantitative Sensory Testing (QST)
Description: Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.

Intervention type: PROCEDURE
Intervention: Quantitative Sensory Testing (QST)
Description: Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.

Intervention type: PROCEDURE
Intervention: Physical Performance
Description: Participants in both groups will have a Physical Performance test.

Intervention type: PROCEDURE
Intervention: Physical Performance
Description: Participants in both groups will have a Physical Performance test.

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants in both groups will have an magnetic resonance imaging (MRI).

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants in both groups will have an magnetic resonance imaging (MRI).

Intervention type: PROCEDURE
Intervention: Blood Sample
Description: Participants in both groups will have blood samples taken.

Intervention type: PROCEDURE
Intervention: Blood Sample
Description: Participants in both groups will have blood samples taken.
Study: NCT03418194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcutaneous acupoint electrical stimulation
Description: Transcutaneous acupoint electrical stimulation(TAES) is a kind of noninvasive therapy similar to acupuncture and moxibustion. Its physiological effect is similar to that of electroacupuncture and hand acupuncture which is a Chinese traditonal therapy using acupuncture.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham transcutaneous acupoint electrical stimulation
Description: Sham transcutaneous acupoint electrical stimulation is the same procedure as transcutaneous acupoint electrical stimulation at points without electronic stimulation.
Study: NCT04620694

Intervention type: DEVICE
Intervention: Choice of arterial cannulation site at the beginning of the surgery
Description: Choice of arterial cannulation site at the beginning of the surgery is at the discretion of the anesthesia physician.
Study: NCT00461110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663513
Description: mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663513
Description: mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks
Study: NCT04387799

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology for Covid-19
Description: Antibody tests designed to provide results to individuals or healthcare providers can show whether someone was previously infected with SARS-CoV-2 being the RT-PCR negative for the population of patients
Study: NCT00694720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0657
Description: capsules once a day at bedtime
Study: NCT03827850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERDAFITINIB
Description: Daily in a range from 3 mg to 9 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERDAFITINIB
Description: Daily in a range from 3 mg to 9 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERDAFITINIB
Description: Daily in a range from 3 mg to 9 mg
Study: NCT03842631

Intervention type: DRUG
Intervention: Timolol Maleate 0.5% Oph Soln
Description: External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.

Intervention type: DRUG
Intervention: Timolol Maleate 0.5% Oph Soln
Description: External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.
Study: NCT01125462

Intervention type: OTHER
Intervention: Quality of Life Questionnaire (FertiQoL)
Description: Subjects will be administered the first internationally validated Quality of Life questionnaire (FertiQoL) to assess the quality of life of infertile subjects.

Intervention type: OTHER
Intervention: Quality of Life Questionnaire (FertiQoL)
Description: Subjects will be administered the first internationally validated Quality of Life questionnaire (FertiQoL) to assess the quality of life of infertile subjects.
Study: NCT01841112

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received matching placebo to the BI-409306 (film-coated tablet/s), administered orally on day 1 for single dose (SD) segment and on day 3 to day 9 for multiple dose (MD) segment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-409306 25 milligram (mg) SD
Description: Subjects received 25 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-409306 50 mg SD
Description: Subjects received 50 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-409306 100 mg SD
Description: Subjects received 100 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-409306 100 mg MD
Description: Subjects received 100 mg multiple dose of BI-409306 (film-coated tablet/s), administered orally once on day 3 to day 9
Study: NCT05168137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose colchicine
Description: prescribed colchicine 0.6 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of colchicine
Study: NCT04114812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended learning
Description: In the intervention group, students will be given access to an e-learning platform that contains five e-learning modules. They will attend individual small group tutoring sessions, with a maximum of 4 students per group. They will be able to book these sessions at a dedicated web platform. They will have 16 weeks in which to complete the 5 e-learning modules and 16 hours of practical training. Progress will be monitored and supported by regular follow-up messages and calls by the study team. Students must hand in the logbook with tutors' signatures when they enter the exam. All students within the blended learning group that completed 5 hours of e-learning as well as 16 hours of peer-tutoring and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard course
Description: In the standard course or control group, students will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training in small groups, with a maximum of 4 students per group. The course will be held in an ultrasound training centre in Bern. All students within the standard course group that participated in the whole 2.5 day course and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
Study: NCT03467698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Real stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham stimulation
Study: NCT02927652

Intervention type: OTHER
Intervention: Questionnaires
Description: New patients at the Duke Clinic 1F and Duke Raleigh Otolaryngology will be asked to complete the Brief Symptom Inventory-18 (BSI-18), patient control scale, and CG-CAHPS.~If a patients answers a 1, 2, 3, or 4 to question #17 (Thoughts of ending your life) on the BSI-18, the nurse will immediately contact the investigator, who will refer for further assessment and/or treatment. The Duke Social Work office is available to provide support, and the Duke Emergency Department has certified social workers and a psychiatric team to do full evaluations if needed.
Study: NCT00623363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: piclozotan
Description: piclozotan, intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride (normal saline)
Description: 0.9% sodium chloride (normal saline) intravenous (IV) infusion
Study: NCT02562144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine spray
Description: Cutaneous xylocaine spray before intravenous cannulation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cutaneous placebo before intravenous cannulation.
Study: NCT04114097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betnovate, betamethasone dipropionate ointment 0.1% and placebo
Description: Explore the systemic effects of Betnovate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic, tacrolimus ointment 0.1%
Description: Compare the systemic effects of Betnovate to Protopic
Study: NCT01138761

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse instruction
Description: The dermatology nurse will give additional verbal and written instruction utilizing teach-back about skin care precautions and medication usage to the caregivers/parents in the treatment group.
Study: NCT02584036

Intervention type: BIOLOGICAL
Intervention: Vaccine administration by a pharmacist
Description: Administration, number and types, of vaccine(s) by a pharmacist

Intervention type: BEHAVIORAL
Intervention: Unmet vaccination needs identified and met
Description: Identification of unmet vaccination needs and having those needs met

Intervention type: BEHAVIORAL
Intervention: Vaccination forecast review and patient education
Description: Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
Study: NCT04706793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
Study: NCT00409591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maternal and infant nevirapine
Description: * In women, one NVP 200 mg tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maternal placebo and infant nevirapine
Description: * In women, one placebo tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours~Comparison between Arms 1 and 2 is double-blinded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maternal lopinavir+ritonavir
Description: - In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zidovudine
Description: In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zidovudine
Description: In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zidovudine
Description: In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
Study: NCT00592462

Intervention type: PROCEDURE
Intervention: Whole Body MRI
Description: The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
Study: NCT00839332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT00456378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAM™ Spinal Stabilization System
Description: Surgical procedure with implantation of the Investigational device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative care
Description: Six months of conservative care, to include: patient education, medications, physical therapy and spinal injections.
Study: NCT03722498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC of FOLFOX
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: administration of Sorafenib
Study: NCT03260803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oligopin
Description: Oligopin ,150 mg ,once daily, 12 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo,150 mg ,once daily, 12 week
Study: NCT01226836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LWWCOPD for Pulmonary Rehabilitation
Description: As part of clinical care participants will attend a 6 week pulmonary rehabilitation programme consisting of supervised exercise and education sessions. The exercise component will be consistent with the usual pulmonary rehabilitation programme delivered at that site (BTS 2001, NICE 2004). The education sessions will be delivered using the revised LWWCOPD programme (1/week, approx. 30-45min). All health professionals will be provided with the health professionals' manual and supplementary posters for their respective education session. All participants will be provided with the revised LWWCOPD information booklet and an action plan for recognising and managing exacerbations.
Study: NCT01108042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
Description: Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
Study: NCT02062645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine/valsartan
Description: Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
Study: NCT01376297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant and Palonosetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT00087555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem (sodium oxybate) oral solution
Description: Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem (sodium oxybate) oral solution
Description: Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one of two doses matching active treatment by volume for 8 weeks.
Study: NCT01113164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron and Sertraline
Description: capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron and Sertraline
Description: capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day
Study: NCT00582114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
Study: NCT00461123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
Study: NCT01233271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space TGC
Description: Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
Study: NCT04186052

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-CART cells
Description: Target BCMA chimeric antigen receptor T cell infusion
Study: NCT04514172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive industrial exoskeleton for back support
Description: The goal is to compare the human response to the simulated industrial tasks
Study: NCT00694720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0657
Description: capsules once a day at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0657
Description: capsules once a day at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0657
Description: capsules once a day at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules once a day at bedtime
Study: NCT01486186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Description: A herbal extract twice daily for 52 weeks for lower dosage, There are 3 Recipe for the 3 traditional Chinese syndrome, they are syndrome of lung-qi deficiency, syndrome of deficiency of pulmonosplenic qi, syndrome of insufficiency of QI of the lung and kidney.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo chinese medicine
Description: There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
Study: NCT00766844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord stimulation
Description: electrode is inserted into cervical epidural space for continuous spinal cord stimulation
Study: NCT03341117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid 300 mg per capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcined magnesia
Description: Calcined magnesia 300 mg per capsule
Study: NCT03737279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Routine care + twice daily meditation per schedule, to start on the day of randomization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: Routine care including ACOG educational pamphlets:~* Day 1: Nutrition in Pregnancy~* Day 2: Heart Health for Women~* Day 3: Exercise after Pregnancy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Routine care including ACOG educational pamphlets:~* Day 1: Nutrition in Pregnancy~* Day 2: Heart Health for Women~* Day 3: Exercise after Pregnancy
Study: NCT02537652

Intervention type: OTHER
Intervention: Blood pressure assessment
Description: Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will take their medication the morning of each assessment in accordance with the normal pharmacological management procedures which are used on the acute stroke ward at the Royal Hampshire County Hospital. Following this, participants will rest supine (on an electrically operated bed) for a minimum of 15 minutes. Oscillometric pressure waveforms (using the SphygmoCor XCEL), recorded on the left upper arm, will assess haemodynamic parameters including central and peripheral blood pressure, pulse pressure, and augmentation index (fasted, supine condition).

Intervention type: OTHER
Intervention: Blood pressure assessment
Description: Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will take their medication the morning of each assessment in accordance with the normal pharmacological management procedures which are used on the acute stroke ward at the Royal Hampshire County Hospital. Following this, participants will rest supine (on an electrically operated bed) for a minimum of 15 minutes. Oscillometric pressure waveforms (using the SphygmoCor XCEL), recorded on the left upper arm, will assess haemodynamic parameters including central and peripheral blood pressure, pulse pressure, and augmentation index (fasted, supine condition).
Study: NCT01118988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentorship
Description: Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
Study: NCT03353948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MET
Description: In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMBI
Description: In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.